Role of isocitrate dehydrogenase in glioma

References

• Parsons DW, Jones S, Zhang X et al. An integrated genomic analysis of human glioblastoma multiforme. Science321(5897), 1807–1812 (2008).
   PubMed Web of Science ®Google Scholar
• Balss J, Meyer J, Mueller W, Korshunov A, Hartmann C, von Deimling A. Analysis of the IDH1 codon 132 mutation in brain tumors. Acta Neuropathol.116(6), 597–602 (2008).
   PubMed Web of Science ®Google Scholar
• Bleeker FE, Atai NA, Lamba S et al. The prognostic IDH1 (R132) mutation is associated with reduced NADP+-dependent IDH activity in glioblastoma. Acta Neuropathol.119(4), 487–494 (2010).
   PubMed Web of Science ®Google Scholar
• Christensen BC, Smith AA, Zheng S et al. DNA methylation, isocitrate dehydrogenase mutation, and survival in glioma. J. Natl Cancer Inst.103(2), 143–153 (2011).
   PubMedGoogle Scholar
• Gravendeel LAM, Kouwenhoven MCM, Gevaert O et al. Intrinsic gene expression profiles of gliomas are a better predictor of survival than histology. Cancer Res.69(23), 9065–9072 (2009).
   PubMed Web of Science ®Google Scholar
• Hartmann C, Meyer J, Balss J et al. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Acta Neuropathol.118(4), 469–474 (2009).
   PubMed Web of Science ®Google Scholar
• Horbinski C, Kofler J, Kelly LM, Murdoch GH, Nikiforova MN. Diagnostic use of IDH1/2 mutation analysis in routine clinical testing of formalin-fixed, paraffin-embedded glioma tissues. J. Neuropathol. Exp. Neurol.68(12), 1319–1325 (2009).
   PubMed Web of Science ®Google Scholar
• Ichimura K, Pearson DM, Kocialkowski S et al. IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas. Neuro Oncol.11(4), 341–347 (2009).
   PubMed Web of Science ®Google Scholar
• Kang MR, Kim MS, Oh JE et al. Mutational analysis of IDH1 codon 132 in glioblastomas and other common cancers. Int. J. Cancer125(2), 353–355 (2009).
   PubMed Web of Science ®Google Scholar
• Korshunov A, Meyer J, Capper D et al. Combined molecular analysis of BRAF and IDH1 distinguishes pilocytic astrocytoma from diffuse astrocytoma. Acta Neuropathol.118(3), 401–405 (2009).
   PubMed Web of Science ®Google Scholar
• Nobusawa S, Watanabe T, Kleihues P, Ohgaki H. IDH1 mutations as molecular signature and predictive factor of secondary glioblastomas. Clin. Cancer Res.15(19), 6002–6007 (2009).
   PubMed Web of Science ®Google Scholar
• Sanson M, Marie Y, Paris S et al. Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. J. Clin. Oncol.27(25), 4150–4154 (2009).
   PubMed Web of Science ®Google Scholar
• Sonoda Y, Kumabe T, Nakamura T et al. Analysis of IDH1 and IDH2 mutations in Japanese glioma patients. Cancer Sci.100(10), 1996–1998 (2009).
   PubMed Web of Science ®Google Scholar
• Watanabe T, Nobusawa S, Kleihues P, Ohgaki H. IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. Am. J. Pathol.174(4), 1149–1153 (2009).
   PubMed Web of Science ®Google Scholar
• Wick W, Hartmann C, Engel C et al. NOA-04 randomized Phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. J. Clin. Oncol.27(35), 5874–5880 (2009).
   PubMed Web of Science ®Google Scholar
• Yan H, Parsons DW, Jin G et al.IDH1 and IDH2 mutations in gliomas. N. Engl. J. Med.360(8), 765–773 (2009).
   PubMed Web of Science ®Google Scholar
• Gravendeel LAM, Kloosterhof NK, Bralten LBC et al. Segregation of non-p. R132H mutations in IDH1 in distinct molecular subtypes of glioma. Hum. Mutat.31(3), E1186–E1199 (2010).
   PubMedGoogle Scholar
• Xu X, Zhao J, Xu Z et al. Structures of human cytosolic NADP-dependent isocitrate dehydrogenase reveal a novel self-regulatory mechanism of activity. J. Biol. Chem.279(32), 33946–33957 (2004).
   PubMed Web of Science ®Google Scholar
• Jennings GT, Sechi S, Stevenson PM, Tuckey RC, Parmelee D, McAlister-Henn L. Cytosolic NADP(+)-dependent isocitrate dehydrogenase. Isolation of rat cDNA and study of tissue-specific and developmental expression of mRNA. J. Biol. Chem.269(37), 23128–23134 (1994).
   PubMed Web of Science ®Google Scholar
• Haselbeck RJ, McAlister-Henn L. Function and expression of yeast mitochondrial NAD- and NADP-specific isocitrate dehydrogenases. J. Biol. Chem.268(16), 12116–12122 (1993).
   PubMed Web of Science ®Google Scholar
• Ramachandran N, Colman RF. Chemical characterization of distinct subunits of pig heart DPN-specific isocitrate dehydrogenase. J. Biol. Chem.255(18), 8859–8864 (1980).
   PubMedGoogle Scholar
• Weller M, Wick W, von Deimling A. Isocitrate dehydrogenase mutations: a challenge to traditional views on the genesis and malignant progression of gliomas. Glia59(8), 1200–1204 (2011).
   PubMedGoogle Scholar
• Keys DA, McAlister-Henn L. Subunit structure, expression, and function of NAD(H)-specific isocitrate dehydrogenase in Saccharomyces cerevisiae. J. Bacteriol.172(8), 4280–4287 (1990).
   PubMed Web of Science ®Google Scholar
• Nekrutenko A, Hillis DM, Patton JC, Bradley RD, Baker RJ. Cytosolic isocitrate dehydrogenase in humans, mice, and voles and phylogenetic analysis of the enzyme family. Mol. Biol. Evol.15(12), 1674–1684 (1998).
   PubMed Web of Science ®Google Scholar
• Luo H, Shan X, Wu J. Expression of human mitochondrial NADP-dependent isocitrate dehydrogenase during lymphocyte activation. J. Cell. Biochem.60(4), 495–507 (1996).
   PubMed Web of Science ®Google Scholar
• Park SY, Lee SM, Shin SW, Park J-W. Inactivation of mitochondrial NADP+-dependent isocitrate dehydrogenase by hypochlorous acid. Free Radic. Res.42(5), 467–473 (2008).
   PubMedGoogle Scholar
• Kloosterhof NK, Bralten LB, Dubbink HJ, French PJ, van den Bent MJ. Isocitrate dehydrogenase-1 mutations: a fundamentally new understanding of diffuse glioma? Lancet Oncol.12(1), 83–91 (2011).
   PubMedGoogle Scholar
• Koh H-J, Lee SM, Son B-G et al. Cytosolic NADP+-dependent isocitrate dehydrogenase plays a key role in lipid metabolism. J. Biol. Chem.279(38), 39968–39974 (2004).
   PubMed Web of Science ®Google Scholar
• Shechter I, Dai P, Huo L, Guan G. IDH1 gene transcription is sterol regulated and activated by SREBP-1a and SREBP-2 in human hepatoma HepG2 cells: evidence that IDH1 may regulate lipogenesis in hepatic cells. J. Lipid Res.44(11), 2169–2180 (2003).
   PubMedGoogle Scholar
• Ronnebaum SM, Ilkayeva O, Burgess SC et al. A pyruvate cycling pathway involving cytosolic NADP-dependent isocitrate dehydrogenase regulates glucose-stimulated insulin secretion. J. Biol. Chem.281(41), 30593–30602 (2006).
   PubMedGoogle Scholar
• Jo SH, Son MK, Koh HJ et al. Control of mitochondrial redox balance and cellular defense against oxidative damage by mitochondrial NADP+-dependent isocitrate dehydrogenase. J. Biol. Chem.276(19), 16168–16176 (2001).
   PubMed Web of Science ®Google Scholar
• Kim J, Kim KY, Jang H-S et al. Role of cytosolic NADP+-dependent isocitrate dehydrogenase in ischemia-reperfusion injury in mouse kidney. Am. J. Physiol. Renal Physiol.296(3), F622–F633 (2009).
   PubMed Web of Science ®Google Scholar
• Kim SY, Park J-W. Cellular defense against singlet oxygen-induced oxidative damage by cytosolic NADP+-dependent isocitrate dehydrogenase. Free Radic. Res.37(3), 309–316 (2003).
   PubMed Web of Science ®Google Scholar
• Lee JH, Kim SY, Kil IS, Park J-W. Regulation of ionizing radiation-induced apoptosis by mitochondrial NADP+-dependent isocitrate dehydrogenase. J. Biol. Chem.282(18), 13385–13394 (2007).
   PubMed Web of Science ®Google Scholar
• Lee SM, Koh H-J, Park D-C, Song BJ, Huh T-L, Park J-W. Cytosolic NADP(+)-dependent isocitrate dehydrogenase status modulates oxidative damage to cells. Free Radic. Biol. Med.32(11), 1185–1196 (2002).
   PubMed Web of Science ®Google Scholar
• Jo S-H, Lee S-H, Chun HS et al. Cellular defense against UVB-induced phototoxicity by cytosolic NADP(+)-dependent isocitrate dehydrogenase. Biochem. Biophys. Res. Commun.292(2), 542–549 (2002).
   PubMed Web of Science ®Google Scholar
• Lee JH, Kim SY, Kil IS, Park J-W. Regulation of ionizing radiation-induced apoptosis by mitochondrial NADP+-dependent isocitrate dehydrogenase. J. Biol. Chem.282(18), 13385–13394 (2007).
   PubMed Web of Science ®Google Scholar
• Lee S-H, Ha S-O, Koh H-J et al. Upregulation of cytosolic NADP+-dependent isocitrate dehydrogenase by hyperglycemia protects renal cells against oxidative stress. Mol. Cells29(2), 203–208 (2010).
   PubMedGoogle Scholar
• Lee SH, Jo SH, Lee SM et al. Role of NADP+-dependent isocitrate dehydrogenase (NADP+-ICDH) on cellular defence against oxidative injury by gamma-rays. Int. J. Radiat. Biol.80(9), 635–642 (2004).
   PubMed Web of Science ®Google Scholar
• Lee SM, Koh H-J, Park D-C, Song BJ, Huh T-L, Park J-W. Cytosolic NADP(+)-dependent isocitrate dehydrogenase status modulates oxidative damage to cells. Free Radic. Biol. Med.32(11), 1185–1196 (2002).
   PubMed Web of Science ®Google Scholar
• Loenarz C, Schofield CJ. Expanding chemical biology of 2-oxoglutarate oxygenases. Nat. Chem. Biol.4(3), 152–156 (2008).
   PubMed Web of Science ®Google Scholar
• Ivan M, Kondo K, Yang H et al. HIFα targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing. Science292(5516), 464–468 (2001).
   PubMed Web of Science ®Google Scholar
• Jaakkola P, Mole DR, Tian YM et al. Targeting of HIF-α to the von Hippel–Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science292(5516), 468–472 (2001).
   PubMed Web of Science ®Google Scholar
• Maxwell PH, Wiesener MS, Chang GW et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature399(6733), 271–275 (1999).
   PubMed Web of Science ®Google Scholar
• Epstein AC, Gleadle JM, McNeill LA et al.C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell107(1), 43–54 (2001).
   PubMed Web of Science ®Google Scholar
• Kivirikko KI, Myllylä R, Pihlajaniemi T. Protein hydroxylation: prolyl 4-hydroxylase, an enzyme with four cosubstrates and a multifunctional subunit. FASEB J.3(5), 1609–1617 (1989).
   PubMed Web of Science ®Google Scholar
• Schofield CJ, Zhang Z. Structural and mechanistic studies on 2-oxoglutarate-dependent oxygenases and related enzymes. Curr. Opin. Struct. Biol.9(6), 722–731 (1999).
   PubMed Web of Science ®Google Scholar
• Myllylä R, Tuderman L, Kivirikko KI. Mechanism of the prolyl hydroxylase reaction. 2. Kinetic analysis of the reaction sequence. Eur. J. Biochem.80(2), 349–357 (1977).
   PubMedGoogle Scholar
• Tuderman L, Myllylä R, Kivirikko KI. Mechanism of the prolyl hydroxylase reaction. 1. Role of co-substrates. Eur. J. Biochem.80(2), 341–348 (1977).
   PubMed Web of Science ®Google Scholar
• Lee S, Nakamura E, Yang H et al. Neuronal apoptosis linked to EglN3 prolyl hydroxylase and familial pheochromocytoma genes: developmental culling and cancer. Cancer Cell8(2), 155–167 (2005).
   PubMed Web of Science ®Google Scholar
• Schlisio S. Neuronal apoptosis by prolyl hydroxylation: implication in nervous system tumours and the Warburg conundrum. J. Cell. Mol. Med.13(10), 4104–4112 (2009).
   PubMed Web of Science ®Google Scholar
• Horbinski C, Kofler J, Yeaney G et al. Isocitrate dehydrogenase 1 analysis differentiates gangliogliomas from infiltrative gliomas. Brain Pathol.21(5), 564–574 (2011).
   PubMed Web of Science ®Google Scholar
• Murugan AK, Bojdani E, Xing M. Identification and functional characterization of isocitrate dehydrogenase 1 (IDH1) mutations in thyroid cancer. Biochem. Biophys. Res. Commun.393(3), 555–559 (2010).
   PubMed Web of Science ®Google Scholar
• Mardis ER, Ding L, Dooling DJ et al. Recurring mutations found by sequencing an acute myeloid leukemia genome. N. Engl. J. Med.361(11), 1058–1066 (2009).
   PubMed Web of Science ®Google Scholar
• Sjöblom T, Jones S, Wood LD et al. The consensus coding sequences of human breast and colorectal cancers. Science314(5797), 268–274 (2006).
   PubMed Web of Science ®Google Scholar
• Lopez G, Reitman Z, Solomon D. IDH1 (R132) mutation identified in one human melanoma metastasis, but not correlated with metastases to the brain. Biochem. Biophys. Res. Commun.398(3), 585–587 (2010).
   PubMed Web of Science ®Google Scholar
• Shibata T, Kokubu A, Miyamoto M, Sasajima Y, Yamazaki N. Mutant IDH1 confers an in vivo growth in a melanoma cell line with BRAF mutation. Am. J. Pathol.178(3), 1395–1402 (2011).
   PubMedGoogle Scholar
• Dubbink HJ, Taal W, van Marion R et al.IDH1 mutations in low-grade astrocytomas predict survival but not response to temozolomide. Neurology73(21), 1792–1795 (2009).
   PubMed Web of Science ®Google Scholar
• van den Bent MJ, Dubbink HJ, Marie Y et al.IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group. Clin. Cancer Res.16(5), 1597–1604 (2010).
   PubMed Web of Science ®Google Scholar
• Labussière M, Idbaih A, Wang X-W et al. All the 1p19q codeleted gliomas are mutated on IDH1 or IDH2. Neurology74(23), 1886–1890 (2010).
   PubMed Web of Science ®Google Scholar
• Weller M, Felsberg J, Hartmann C et al. Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network. J. Clin. Oncol.27(34), 5743–5750 (2009).
   PubMed Web of Science ®Google Scholar
• Verhaak RGW, Hoadley KA, Purdom E et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell17(1), 98–110 (2010).
   PubMed Web of Science ®Google Scholar
• Noushmehr H, Weisenberger DJ, Diefes K et al. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell17(5), 510–522 (2010).
   PubMed Web of Science ®Google Scholar
• Watanabe T, Vital A, Nobusawa S, Kleihues P, Ohgaki H. Selective acquisition of IDH1 R132C mutations in astrocytomas associated with Li–Fraumeni syndrome. Acta Neuropathol.117(6), 653–656 (2009).
   PubMedGoogle Scholar
• Zhao S, Lin Y, Xu W et al. Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1α. Science324(5924), 261–265 (2009).
   PubMed Web of Science ®Google Scholar
• Pusch S, Sahm F, Meyer J, Mittelbronn M, Hartmann C, von Deimling A. Scientific correspondence. Neuropathol. Appl. Neurobiol.37(4), 428–430 (2011).
   PubMedGoogle Scholar
• Jin G, Reitman ZJ, Spasojevic I et al. 2-hydroxyglutarate production, but not dominant negative function, is conferred by glioma-derived NADP-dependent isocitrate dehydrogenase mutations. PLoS ONE6(2), e16812 (2011).
   PubMed Web of Science ®Google Scholar
• Ward PS, Patel J, Wise DR et al. The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting α-ketoglutarate to 2-hydroxyglutarate. Cancer Cell17(3), 225–234 (2010).
   PubMed Web of Science ®Google Scholar
• Dang L, White DW, Gross S et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature462(7274), 739–744 (2009).
   PubMed Web of Science ®Google Scholar
• Chalmers RA, Lawson AM, Watts RW et al. D-2-hydroxyglutaric aciduria: case report and biochemical studies. J. Inherit. Metab. Dis.3(1), 11–15 (1980).
   PubMedGoogle Scholar
• van der Knaap MS, Jakobs C, Hoffmann GF et al. D-2-hydroxyglutaric aciduria: further clinical delineation. J. Inherit. Metab. Dis.22(4), 404–413 (1999).
   PubMedGoogle Scholar
• Kranendijk M, Struys EA, van Schaftingen E et al.IDH2 mutations in patients with D-2-hydroxyglutaric aciduria. Science330(6002), 336 (2010).
   PubMed Web of Science ®Google Scholar
• Duran M, Kamerling JP, Bakker HD, van Gennip AH, Wadman SK. L-2-hydroxyglutaric aciduria: an inborn error of metabolism? J. Inherit. Metab. Dis.3(4), 109–112 (1980).
   PubMedGoogle Scholar
• Van Schaftingen E, Rzem R, Veiga-da-Cunha M. L: -2-Hydroxyglutaric aciduria, a disorder of metabolite repair. J. Inherit. Metab. Dis.32(2), 135–142 (2009).
   PubMed Web of Science ®Google Scholar
• Reitman ZJ, Jin G, Karoly ED et al. Profiling the effects of isocitrate dehydrogenase 1 and 2 mutations on the cellular metabolome. Proc. Natl Acad. Sci. USA108(8), 3270–3275 (2011).
   PubMed Web of Science ®Google Scholar
• Kölker S, Pawlak V, Ahlemeyer B et al. NMDA receptor activation and respiratory chain complex V inhibition contribute to neurodegeneration in D-2-hydroxyglutaric aciduria. Eur. J. Neurosci.16(1), 21–28 (2002).
   PubMed Web of Science ®Google Scholar
• Yen KE, Bittinger MA, Su SM, Fantin VR. Cancer-associated IDH mutations: biomarker and therapeutic opportunities. Oncogene29(49), 6409–6417 (2010).
   PubMed Web of Science ®Google Scholar
• Xu W, Yang H, Liu Y et al. Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases. Cancer Cell19(1), 17–30 (2011).
   PubMed Web of Science ®Google Scholar
• Pappalardi MB, McNulty DE, Martin JD et al. Biochemical characterization of human HIF hydroxylases using HIF protein substrates that contain all three hydroxylation sites. Biochem. J.436(2), 363–369 (2011).
   PubMedGoogle Scholar
• Toedt G, Barbus S, Wolter M et al. Molecular signatures classify astrocytic gliomas by IDH1 mutation status. Int. J. Cancer128(5), 1095–1103 (2011).
   PubMed Web of Science ®Google Scholar
• Metellus P, Colin C, Taieb D et al.IDH mutation status impact on in vivo hypoxia biomarkers expression: new insights from a clinical, nuclear imaging and immunohistochemical study in 33 glioma patients. J. Neurooncol. DOI: 10.1007/s11060-011-0625-2 (2011) (Epub ahead of print).
   Google Scholar
• Williams SC, Karajannis MA, Chiriboga L, Golfinos JG, Deimling A, Zagzag D. R132H-mutation of isocitrate dehydrogenase-1 is not sufficient for HIF-1α upregulation in adult glioma. Acta Neuropathol.121(2), 279–281 (2010).
   PubMedGoogle Scholar
• Basanta D, Scott JG, Rockne R, Swanson KR, Anderson ARA. The role of IDH1 mutated tumour cells in secondary glioblastomas: an evolutionary game theoretical view. Phys. Biol.8(1), 015016 (2011).
   PubMedGoogle Scholar
• Krieg AJ, Rankin EB, Chan D, Razorenova O, Fernandez S, Giaccia AJ. Regulation of the histone demethylase JMJD1A by hypoxia-inducible factor 1α enhances hypoxic gene expression and tumor growth. Mol. Cell Biol.30(1), 344–353 (2010).
   PubMed Web of Science ®Google Scholar
• Chowdhury R, Yeoh KK, Tian Y-M et al. The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases. EMBO Rep.12(5), 463–469 (2011).
   PubMed Web of Science ®Google Scholar
• Figueroa ME, Lugthart S, Li Y et al. DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia. Cancer Cell17(1), 13–27 (2010).
   PubMed Web of Science ®Google Scholar
• Dinchuk JE. Absence of post-translational aspartyl β-hydroxylation of epidermal growth factor domains in mice leads to developmental defects and an increased incidence of intestinal neoplasia. J. Biol. Chem.277(15), 12970–12977 (2001).
   PubMedGoogle Scholar
• Capper D, Weissert S, Balss J et al. Characterization of R132H mutation-specific IDH1 antibody binding in brain tumors. Brain Pathol.20(1), 245–254 (2010).
   PubMed Web of Science ®Google Scholar
• Metellus P, Coulibaly B, Colin C et al. Absence of IDH mutation identifies a novel radiologic and molecular subtype of WHO grade II gliomas with dismal prognosis. Acta Neuropathol.120(6), 719–729 (2010).
   PubMed Web of Science ®Google Scholar
• Houillier C, Wang X, Kaloshi G et al.IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas. Neurology75(17), 1560–1566 (2010).
   PubMed Web of Science ®Google Scholar
• Seiz M, Tuettenberg J, Meyer J et al. Detection of IDH1 mutations in gliomatosis cerebri, but only in tumors with additional solid component: evidence for molecular subtypes. Acta Neuropathol.120(2), 261–267 (2010).
   PubMedGoogle Scholar
• Hartmann C, Hentschel B, Wick W et al. Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas. Acta Neuropathol.120(6), 707–718 (2010).
   PubMed Web of Science ®Google Scholar
• Kil IS, Kim SY, Lee SJ, Park J-W. Small interfering RNA-mediated silencing of mitochondrial NADP+-dependent isocitrate dehydrogenase enhances the sensitivity of HeLa cells toward tumor necrosis factor-α and anticancer drugs. Free Radic. Biol. Med.43(8), 1197–1207 (2007).
   PubMedGoogle Scholar
• Matsumoto K, Obara N, Ema M et al. Antitumor effects of 2-oxoglutarate through inhibition of angiogenesis in a murine tumor model. Cancer Sci.100(9), 1639–1647 (2009).
   PubMed Web of Science ®Google Scholar
• Seltzer MJ, Bennett BD, Joshi AD et al. Inhibition of glutaminase preferentially slows growth of glioma cells with mutant IDH1. Cancer Res.70(22), 8981–8987 (2010).
   PubMed Web of Science ®Google Scholar
• Dang L, Jin S, Su SM. IDH mutations in glioma and acute myeloid leukemia. Trends Mol. Med.16(9), 387–397 (2010).
   PubMed Web of Science ®Google Scholar
• Pollack IF, Hamilton RL, Sobol RW et al.IDH1 mutations are common in malignant gliomas arising in adolescents: a report from the Children’s Oncology Group. Childs Nerv. Syst.27(1), 87–94 (2011).
   PubMedGoogle Scholar